This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (5) Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Fleming, T. R Articles by Stewart, R. Search for Related Content PubMed PubMed Citation Articles by Fleming, T. R Articles by Stewart, R. Pubmed/NCBI databases Medline Plus Health Information Clinical Trials Social Bookmarking                         What's this?

Maintaining confidentiality of interim data to enhance trial integrity and credibility

Department of Biostatistics, University of Washington, Seattle, WA, USA, tfleming{at}u.washington.edu

Katrina Sharples

Department of Preventive and Social Medicine, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand

John McCall

Department of Surgery, School of Medical and Health Sciences, University of Auckland, Auckland, New Zealand

Andrew Moore

Department of Philosophy, University of Otago, Dunedin, New Zealand

Anthony Rodgers

Clinical Trials Research Unit, University of Auckland, Auckland, New Zealand

Ralph Stewart

Cardiologist and Associate Professor, Green Lane Cardiovascular Service, Auckland City Hospital, Auckland, New Zealand

Background For clinical trials of interventions that could affect mortality or major morbidity, Data Monitoring Committees have an important role in safeguarding patient interests and enhancing trial integrity and credibility. In trials overseen by an independent DMC it is widely recognized that interim data should remain confidential to the DMC and to the statistical group preparing reports. However, we have found that the principle of confidentiality is not always followed in practice, particularly where the interim data include complete results on a short-term outcome measure.

Purpose To discuss the reasoning and evidence supporting the principle of confidentiality of interim data with emphasis on the setting where the interim data include complete results on a short-term outcome.

Methods We review the reasons why wider access to interim data can increase the risk of false positive or false negative conclusions and discuss the types of harm which can occur. We provide illustrations and insights from recent experiences and discuss the level of consensus in the research community.

Results The arguments in favor of early release of interim data include the need to provide reliable data in a timely manner to patients and physicians, the potential to increase the enthusiasm of trial investigators, and to restore equipoise. However interim data, even where these include complete results on a short-term outcome measure, provide an unreliable and biased assessment of the overall benefit-to-risk profile of the trial treatments. Pre-judgment based on over-interpretation of such interim data can affect recruitment, treatment delivery, and follow-up, risking the ability of the trial to achieve its goals.

Conclusions In order to preserve the integrity of a trial and safeguard the interests of patients, interim data, including complete data on short-term outcomes, should remain confidential to the DMC and the statistical group responsible for preparing interim reports until the trial has achieved its primary objectives. Clinical Trials 2008; 5: 157—167. http://ctj.sagepub.com

Clinical Trials, Vol. 5, No. 2, 157-167 (2008)
DOI: 10.1177/1740774508089459


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				T. R. Fleming Identifying and Addressing Safety Signals in Clinical Trials N. Engl. J. Med., September 25, 2008; 359(13): 1400 - 1402. [Full Text] [PDF]